These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 28833621

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, Wagg A.
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [Abstract] [Full Text] [Related]

  • 3. Long-term persistence with mirabegron in a real-world clinical setting.
    Wada N, Watanabe M, Banjo H, Tsuchida M, Hori J, Tamaki G, Azumi M, Kita M, Kakizaki H.
    Int J Urol; 2018 May; 25(5):501-506. PubMed ID: 29651798
    [Abstract] [Full Text] [Related]

  • 4. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
    Nazir J, Hakimi Z, Guelfucci F, Khemiri A, Fatoye F, Blázquez AMM, González MH.
    BMC Urol; 2018 Sep 04; 18(1):76. PubMed ID: 30180826
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database.
    Wagg AS, Foley S, Peters J, Nazir J, Kool-Houweling L, Scrine L.
    Int J Clin Pract; 2017 Oct 04; 71(10):. PubMed ID: 28906080
    [Abstract] [Full Text] [Related]

  • 7. Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.
    Hakimi Z, Nazir J, McCrea C, Berling M, Fatoye F, Ramos B, Wagg A.
    J Med Econ; 2017 Jun 04; 20(6):614-622. PubMed ID: 28286993
    [Abstract] [Full Text] [Related]

  • 8. Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study.
    Chastek B, Carrera A, Landis C, Snyder D, Abedinzadeh L, Bancroft T, Nesheim J, Kennelly M, Staskin D.
    Neurourol Urodyn; 2024 Sep 04; 43(7):1504-1513. PubMed ID: 38720543
    [Abstract] [Full Text] [Related]

  • 9. Mirabegron has longer treatment persistence than antimuscarinics: Real-world data from a Korean national cohort database.
    Lee KS, Park H, Kang D, Byun HJ, Foo CY, Hadi FA, Kim S, Cho J.
    Neurourol Urodyn; 2021 Nov 04; 40(8):1972-1980. PubMed ID: 34486168
    [Abstract] [Full Text] [Related]

  • 10. Anticholinergic burden in the Japanese elderly population: Use of antimuscarinic medications for overactive bladder patients.
    Yoshida M, Kato D, Nishimura T, Van Schyndle J, Uno S, Kimura T.
    Int J Urol; 2018 Oct 04; 25(10):855-862. PubMed ID: 30069973
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.
    Hoffman V, Hallas J, Linder M, Margulis AV, Suehs BT, Arana A, Phiri K, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD, mirabegron PMR-PASS study group.
    Drug Saf; 2021 Aug 04; 44(8):899-915. PubMed ID: 34236595
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Overactive bladder medication: Persistence, drug switching, and reinitiation.
    Soda T, Tashiro Y, Koike S, Ikeuchi R, Okada T.
    Neurourol Urodyn; 2020 Nov 04; 39(8):2527-2534. PubMed ID: 32985716
    [Abstract] [Full Text] [Related]

  • 15. A Nordic registry-based study of drug treatment patterns in overactive bladder patients.
    Milsom I, Schiotz HA, Svensson M, Kilany S, Hansson F.
    Scand J Urol; 2019 Aug 04; 53(4):246-254. PubMed ID: 31195868
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
    Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I, Hakimi Z.
    Eur Urol; 2014 Apr 04; 65(4):755-65. PubMed ID: 24275310
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study.
    Katoh T, Igawa Y, Yamaguchi O, Kato D, Hamada T, Kuroishi K.
    Low Urin Tract Symptoms; 2020 Jan 04; 12(1):68-80. PubMed ID: 31571403
    [Abstract] [Full Text] [Related]

  • 19. A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.
    Bunniran S, Davis C, Kristy R, Ng D, Schermer CR, Uribe C, Suehs BT.
    Neurourol Urodyn; 2018 Jan 04; 37(1):177-185. PubMed ID: 28370541
    [Abstract] [Full Text] [Related]

  • 20. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL, Chen TC, Chang HM, Juan YS, Huang WH, Pan HF, Chang YC, Wu CM, Wang YL, Lee HY.
    World J Urol; 2018 Aug 04; 36(8):1285-1297. PubMed ID: 29556972
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.